-
Art Student Brings Her Talent to the New Medical Education Building
The project represents a gift from the Kirk Kerkorian School of Medicine at UNLV Class of 2022 and the theme of 'diversity, inclusion, and acceptance.'
Checking in on Charter Class Graduate Alex Ma
Medical school alum and second-year resident entertains pediatric hospital patients by volunteering for local nonprofit Critical Care Comics.
Rewriting Nevada's Mining Story
With a rich store of lithium in our lands, the state has a chance to capitalize on the ever-growing demand for clean energy. Here’s how we can ensure this boom doesn’t go bust.
The Interview: Jerra Strong
This entertainment engineering and design alum knows all the tricks when it comes to keeping UNLV’s website accessibility-friendly.
Nevada Conservatory Theatre Opens 'Crumbs from the Table of Joy' Dec. 9
This heartwarming memory play by two-time Pulitzer Prize-winning playwright Lynn Nottage runs in the Judy Bayley Theatre on Dec. 9-18.
UNLV Experts In The News
The Las Vegas showgirl was beautiful, majestic, and larger than life. In full feathers and heels, a showgirl could measure 10 feet tall. She exuded poise and panache, and her revealing costume was bedecked in glimmering Parisian crystals and expensive fur. She was a city icon who helped Las Vegas become the Entertainment Capital of the World.The showgirl is a distant memory for most, but there is hope that she will one day return to the stage.
Newly announced findings from the phase 3 ACCORD trial (NCT04797715) showed that AXS-05 (Axsome Therapeutics), a novel, investigational n-methyl-D-aspartate (NMDA) receptor antagonist, met its primary end point of statistically significant delay in time to relapse and preventing relapse of agitation in patients with Alzheimer disease (AD) agitation.1
Biopharmaceutical company Axsome Therapeutics Inc. (AXSM:NASDAQ), which is focused on developing new medicines for use in the treatment of central nervous system (CNS) disorders, today announced that "AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation) Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer's disease, as compared to placebo."
Don’t Let Cyber Grinches Spoil Your Online Shopping
UNLV security expert shares tips to avoid scams while shopping online during Cyber Monday and the rest of the holiday season.
Research in Brief: Have Humans Wreaked Too Much Havoc on Marine Life to Halt Damage?
UNLV analysis challenges the idea that ocean ecosystems have barely changed over millions of years, pointing scientists down a new path on conservation efforts and policy.
Creating Leaders for Careers in Emergency Crisis Management
UNLV master's program prepares professionals for wide variety of positions serving the community.
UNLV Jazz Ensembles Perform in Annual Fall Festival Nov. 28-30
The jazz studies program recently received its 14th consecutive outstanding review from respected magazine Jazz Times.
How Much Will Inflation Really Influence Spending This Holiday Season?
UNLV consumer behavior and hospitality expert Amanda Belarmino shares predictions on 2022 gift-giving, travel, entertainment, and shopping habits.
Get Our Weekly Newsletter
The "From the News Center" newsletter highlights the top articles, videos, photo galleries, and event information. It is emailed to subscribers on Thursdays.